In vitro acoustic molecular imaging of tissue factor expressed by smooth muscle cells with stable liquid perfluorocarbon nanoparticle contrast agents

Jon N. Marsh, Kathryn C. Crowder, Michael S. Hughes, Michael J. Scott, Elizabeth K. Lacy, Gregory M. Lanza, Samuel A. Wickline

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Scopus citations

Abstract

Liquid perfluorocarbon nanoparticle contrast agents can be used to target specific tissue types through incorporation of appropriate ligands into the nanoparticles' outer lipid monolayer. In this study we sought to characterize the specificity of targeting of perfluorooctyl bromide (PFOB) nanoparticles to tissue factor, a transmembrane glycoprotein expressed by smooth muscle cells as part of inflammatory response after vessel injury (e.g., angioplasty). Porcine smooth muscle cells constitutively expressing tissue factor on the cell surface were cultured on microporous membranes and targeted with PFOB nanoparticles by avidin-biotin binding techniques. Treatment groups included: 1) "targeted" cell samples exposed sequentially to biotinylated tissue factor antibody/avidin/biotinlyated nanoparticles; 2) "non-targeted" smooth muscle cells exposed to avidin/biotinlyated nanoparticles; 3) "control" smooth muscle cells left untreated. Ultrasonic imaging and quantification of surface reflectivity for each cell group was accomplished by scanning a 25MHz transducer in a grid over the membrane inserts and analyzing the reflected RF signal from the cell-covered surfaces. Total PFOB content for each sample (directly related to nanoparticle concentration) was determined independently by gas chromatography. Targeted cells exhibited significantly enhanced surface reflectivity (-22.6±2.0 dB referenced to steel reflector, p<0.002) relative to either non-targeted (-29.6±1.1 dB) or control groups (29.3±1.4 dB). Gas chromatography data indicated that bound PFOB was present in targeted cells at levels nearly six times greater than for nontargeted cells. Additionally, bound PFOB levels for the targeted samples correlated directly with the magnitude of surface reflectivity (r=0.99; p<0.03). In conclusion, PFOB nanoparticles targeted to smooth muscle cell tissue factor specifically bind to such cells at levels nearly six times greater than to nontargeted cells. The targeted cells exhibit substantially enhanced acoustic reflectivity, thereby confirming the utility of quantitative ultrasonic molecular imaging with the use of a nongaseous nanoparticle contrast agent.

Original languageEnglish
Title of host publicationProceedings - 2004 IEEE Ultrasonics Symposium
Subtitle of host publicationA Conference of the IEEE International Ultrasonics, Ferroelectrics, and Frequency Control Society, UFFC-S
EditorsM.P. Yuhas
Pages1102-1105
Number of pages4
DOIs
StatePublished - Dec 1 2004
Event2004 IEEE Ultrasonics Symposium - Montreal, Que., Canada
Duration: Aug 23 2004Aug 27 2004

Publication series

NameProceedings - IEEE Ultrasonics Symposium
Volume2
ISSN (Print)1051-0117

Conference

Conference2004 IEEE Ultrasonics Symposium
CountryCanada
CityMontreal, Que.
Period08/23/0408/27/04

Keywords

  • Contrast agent
  • Liquid emulsion
  • Nanoparticle
  • Perfluorocarbon
  • Targeting
  • Tissue factor

Fingerprint Dive into the research topics of 'In vitro acoustic molecular imaging of tissue factor expressed by smooth muscle cells with stable liquid perfluorocarbon nanoparticle contrast agents'. Together they form a unique fingerprint.

  • Cite this

    Marsh, J. N., Crowder, K. C., Hughes, M. S., Scott, M. J., Lacy, E. K., Lanza, G. M., & Wickline, S. A. (2004). In vitro acoustic molecular imaging of tissue factor expressed by smooth muscle cells with stable liquid perfluorocarbon nanoparticle contrast agents. In M. P. Yuhas (Ed.), Proceedings - 2004 IEEE Ultrasonics Symposium: A Conference of the IEEE International Ultrasonics, Ferroelectrics, and Frequency Control Society, UFFC-S (pp. 1102-1105). [U1-J-3] (Proceedings - IEEE Ultrasonics Symposium; Vol. 2). https://doi.org/10.1109/ULTSYM.2004.1417972